Details for New Drug Application (NDA): 204326
✉ Email this page to a colleague
The generic ingredient in ADZENYS XR-ODT is amphetamine. There are fifty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amphetamine profile page.
Summary for 204326
| Tradename: | ADZENYS XR-ODT |
| Applicant: | Neos Theraps |
| Ingredient: | amphetamine |
| Patents: | 5 |
Pharmacology for NDA: 204326
| Physiological Effect | Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for 204326
Suppliers and Packaging for NDA: 204326
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326 | NDA AUTHORIZED GENERIC | Neos Therapeutics, LP | 62542-005 | 62542-005-30 | 30 BLISTER PACK in 1 CARTON (62542-005-30) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
| ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326 | NDA AUTHORIZED GENERIC | Neos Therapeutics, LP | 62542-010 | 62542-010-30 | 30 BLISTER PACK in 1 CARTON (62542-010-30) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Strength | EQ 3.1MG BASE | ||||
| Approval Date: | Jan 27, 2016 | TE: | AB | RLD: | Yes | ||||
| Patent: | 8,709,491 | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 8,840,924 | Patent Expiration: | Apr 9, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 9,017,731 | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
